Supplementary Table 1. Linear regression model for predictors of RSV knowledge score (excluding licensure item).

Variable	β coefficient	95% CI	p-value
Intercept	6.78	5.57 to 7.99	<0.001
Professional status			
Resident (ref)	1.00	—	—
Specialist	−0.30	−1.06 to 0.47	0.450
Faculty member	−0.23	−1.32 to 0.86	0.680
General practitioner	−1.39	−2.51 to −0.26	0.016
Specialty			
Infectious diseases (ref)	1.00	—	—
Internal medicine	−0.07	−1.34 to 1.19	0.910
Pulmonary diseases	−0.31	−1.74 to 1.12	0.670
Family medicine	+0.26	−1.03 to 1.55	0.700
Other specialties	−0.67	−1.96 to 0.63	0.310
Years of experience			
0–5 years (ref)	1.00	—	—
6–10 years	+0.66	−0.11 to 1.43	0.093
11–15 years	+0.64	−0.28 to 1.57	0.180
≥16 years	+0.45	−0.49 to 1.39	0.350
Knows the license information	+1.00	+0.50 to +1.50	<0.001

Model summary: Adjusted R2 = 0.22. Overall p < 0.001. RSV, respiratory syncytial virus; CI, confidence interval.

Supplementary Table 2. The vaccines recommended by participants in the past 3 months (n = 223).

Vaccine type	n	%
Pneumococcal (PPSV23 or PCV15/PCV20)	146	65.5
Influenza (IIV/LAIV4/RIV4)	129	57.8
Hepatitis B	113	50.7
Tetanus/diphtheria toxoids (Td)	75	33.6
Tetanus–diphtheria–pertussis (Tdap)	32	14.3
Herpes zoster	60	26.9
Hepatitis A	37	16.6
Meningococcal (MenACWY/MenB)	55	24.7
Measles–mumps–rubella (MMR)	19	8.5
Varicella (VAR)	10	4.5
COVID-19	10	4.5
RSV	23	10.3
None (no vaccine recommended)	29	13.0

COVID-19, coronavirus disease 2019; VAR, varicella vaccine; RSV, respiratory syncytial virus.

Supplementary Table 3. General barriers to vaccination among physicians (n = 223).

Reason	n	%
"I do recommend vaccines" (no barrier reported)	159	71.3
Not systematically reviewing patients' vaccination records	34	15.2
Lack of institutional protocols/routine recommendations	25	11.2
Reimbursement/coverage issues	20	9.0
Most patients receive vaccines elsewhere.	14	6.3
Limited vaccine availability at the workplace	14	6.3
Patients not eligible for vaccination	6	2.7

Supplementary Table 4. RSV vaccination attitudes and practice.

Believes that RSV vaccination should definitely be administered in adults ≥60 years	98 (43.9)
Recommended RSV vaccine to ≥1 patient in the past 3 months	23 (10.3)
Did not recommend the RSV vaccine	184 (82.5)
Cannot recall	16 (7.2)
Reports RSV vaccine not available in their institution	171 (76.7)
Aware that RSV vaccination is licensed for adults ≥60 years	95 (42.6)
Aware that the RSV vaccine is currently available in Türkiye	70 (31.4)

RSV, respiratory syncytial virus.

Supplementary Table 5. Main barriers to RSV vaccination by professional status.

Barrier	Resident (n = 72)	Specialist (n = 106)	Faculty (n = 23)	General practitioner (n = 22)	p-value
Patient reluctance	20.8%	28.3%	8.7%	36.4%	0.107
Lack of knowledge	81.9%	75.5%	60.9%	68.2%	0.180
Cost/reimbursement issues	27.8%	42.5%	65.2%	40.9%	0.012
Accessibility	40.3%	50.9%	17.4%	36.4%	0.023
Low personal priority	18.1%	15.1%	17.4%	18.2%	0.950

RSV, respiratory syncytial virus.

Supplementary Table 6. Main barriers to RSV vaccination by specialty.

Barrier	Infectious diseases (n = 108)	Internal medicine (n = 28)	Pulmonary (n = 15)	Family medicine (n = 35)	Other (n = 37)	p-value
Patient reluctance	24.1%	25.0%	33.3%	37.1%	10.8%	0.117
Lack of knowledge	67.6%	85.7%	73.3%	80.0%	86.5%	0.091
Cost/reimbursement issues	47.2%	39.3%	53.3%	45.7%	8.1%	<0.001
Accessibility	48.1%	35.7%	40.0%	40.0%	35.1%	0.577
Low personal priority	14.8%	14.3%	33.3%	14.3%	18.9%	0.452

RSV, respiratory syncytial virus.